Oncolytics Biotech (NASDAQ:ONCY – Get Rating) and Inhibitor Therapeutics (OTCMKTS:INTI – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership.
Earnings & Valuation
This table compares Oncolytics Biotech and Inhibitor Therapeutics’ top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Oncolytics Biotech | N/A | N/A | -$19.10 million | ($0.30) | -6.83 |
| Inhibitor Therapeutics | N/A | N/A | $12.11 million | N/A | N/A |
Risk and Volatility
Analyst Recommendations
This is a summary of current recommendations and price targets for Oncolytics Biotech and Inhibitor Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Oncolytics Biotech | 0 | 0 | 4 | 0 | 3.00 |
| Inhibitor Therapeutics | 0 | 0 | 0 | 0 | N/A |
Oncolytics Biotech presently has a consensus price target of $4.00, indicating a potential upside of 95.12%. Given Oncolytics Biotech’s higher probable upside, analysts plainly believe Oncolytics Biotech is more favorable than Inhibitor Therapeutics.
Institutional & Insider Ownership
1.2% of Oncolytics Biotech shares are held by institutional investors. 0.1% of Oncolytics Biotech shares are held by company insiders. Comparatively, 4.6% of Inhibitor Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Profitability
This table compares Oncolytics Biotech and Inhibitor Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Oncolytics Biotech | N/A | -86.46% | -63.46% |
| Inhibitor Therapeutics | N/A | 22,323.86% | 203.64% |
About Oncolytics Biotech
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
About Inhibitor Therapeutics
Inhibitor Therapeutics, Inc. engages in the discovery, development, and commercialization of therapeutics for patients with cancer. It focuses on SUBA-Itraconazole, a patented, oral formulation of Itraconazole, for treatment of prostate and lung cancers. The company was founded on September 30, 1992 and is headquartered in Tampa, FL.
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
